News

A cohort study showed that those with relapse activity who received DMTs accounted for a greater percent of time with a reduced Multiple Sclerosis Severity Score progression slope during SPMS.

The medical director of the New England Institute for Neurology and Headache and chief medical officer of the New England Institute for Clinical Research detailed the end points and long-term goals of the phase 2 JUNIPER upper limb spasticity trial.

Trial data suggest that management of vitamin D deficiency should be considered in patients with frequent attacks of benign paroxysmal positional vertigo.

Future studies are needed to determine the preferential antihypertensive medication in patients after experiencing a stroke, despite the results suggesting a gap in secondary prevention of stroke.

The full data from the ASCLEPIOS I and II trials suggest that the Novartis agent ofatumumab is superior to teriflunomide in reducing annualized relapse rates and other measurements of disease progression in MS.

Future studies may validate the use of routine electroencephalogram as an alternative to continuous electroencephalogram in centers with limited resources, as despite better seizure detection with continuous monitoring, outcomes were similar between the methods.

The director emeritus of the Lou Ruvo Center for Brain Health at Cleveland Clinic and vice chair of the Department of Brain Health at the University of Nevada–Las Vegas discussed the leading challenges for those with Alzheimer disease.

Adding to a flurry of pipeline movement since July, 2 more rare disease agents—VTA-110 for DMD and arimoclomol for NPC—have made positive steps in their clinical development recently.

Neurology News Network for the week ending August 8, 2020.

The agent, marketed under the brand name Evrysdi, is the first at-home therapy indicated for treatment of adults and children with SMA.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 7, 2020.

Kathleen Digre, MD, past president of the American Headache Society, discusses the barriers to correct identification and treatment of eye symptoms in people with migraine.

The director of the Center for Neurological Restoration at Cleveland Clinic detailed the recent technological and therapeutic innovations and their advantages in treating Parkinson disease.

A PDUFA date has been scheduled for March 7, 2021, but the agency said it would consider an even more expedited review if warranted.

AUPN Leading Edge Episode 1 features Clifton L. Gooch, MD, who discusses this new podcast series from AUPN. [LISTEN TIME: 1 minute]

Marinus Pharmaceuticals, the agent’s manufacturer, plans to announce topline data from the phase 3 Marigold study in the third quarter of this year.

Katrina Celis, MD, a postdoctoral fellow at the University of Miami Miller School of Medicine, discussed how ancestral genetics can play a key role in Alzheimer disease risk.

The investigators wrote that the Alzheimer’s Association “Part the Cloud” funded 24-week treatment trial is now warranted after sargramostim showed a safe and tolerable profile.

Through a joint initiative with Bill Gates, a $3.3 million funding influx will go toward the Strategically Focused Research Network on Health Technologies and Innovation program’s fifth network center.

The director of the Sagol Center for Hyperbaric Medicine and Research at Yitzhak Shamir Medical Center discussed the history of the research and offered insight into the attempt to regenerate injured tissue in the brain.

The co-director of the Neurological Clinical Research Institute at Massachusetts General Hospital spoke to the need for more collaborative efforts in ALS research.

Data from 2 posters presented at AAIC 2020 suggest that there is an unmet need for safe and effective treatments for patients who experience dementia-related psychosis.

The director of the Memory Disorders Program and professor of neurology at Georgetown University Medical Center detailed the phase 2 study findings of nilotinib in patients with Alzheimer disease.

An overview of the tweet chat on mental health in neurological disorders, featuring highlighted contributions from the medical community.

The findings suggest that plasma exchange has the potential to offer patients with Alzheimer disease a new modality of treatment, though additional studies are needed to further investigate the current areas of uncertainty.

Results from the ATLAS Posterior PMA trial demonstrated that physicians can now address the more difficult posterior circulation aneurysms, offering hope for better outcomes in that patient population.

Excessive alcohol intake, head injury, and air pollution are among the newest dementia risk factors added to the Lancet Commission report.

The approval also expands the age range of all Epidiolex indications to include patients age 1 and older.

NeuroPace’s FDA-approved neurostimulation device helped 35% of patients with epilepsy achieve ≥90% reduction in seizure frequency, with 18% of patients reporting seizure freedom at last follow-up.

The director of the Memory Disorders Program and professor of neurology at Georgetown University Medical Center details his findings from the phase 2 study of nilotinib in patients with Alzheimer disease.